HSBC

Glenmark Pharmaceuticals sealed its debut $200m international bond at a yield of 4.5% on Monday, which bankers on the deal said was the tightest pricing achieved by an Indian high yield name.

CDB Capital, a wholly-owned subsidiary of China Development Bank Corp, is looking to raise as much as $500m from a new deal while unrated China Minsheng Investment Corp has returned for a three year bond, with both relying on keepwell structures.

Kookmin Bank opted for an unusual three year bond this week to diversify its funding avenues. The bond found strong interest from offshore accounts eager to get their hands on the new deal, allowing the lender to price inside fair value.

Singapore’s Noble Group has sown up its S$719m ($522m) rights offering with a 173.7% oversubscription, according to a stock exchange filing on Monday.

A stream of dollar issuance over the last few weeks looks like it will keep flowing right into this Wednesday’s US Federal Reserve meeting, after a pair of borrowers mandated on Monday for no-grow $1bn deals.

Petrochemical manufacturer Ineos on Monday launched a €1.1bn-equivalent refinancing deal into a high yield market that has thrown caution to the wind.

South Korea’s Kookmin Bank and Indian’s Glenmark Pharmaceuticals ventured out to the dollar debt market on Monday with their respective bonds.

The government of Sri Lanka’s $300m three year borrowing has received a chunky commitment in syndication, according to a source.

Real estate developer Greenland Hong Kong sold a highly popular bond on Thursday, in a move that highlighted investors’ lack of concern about the issuer’s high leverage.

China Railway Group raised $500m effortlessly from its first dollar bond in more than two years, taking advantage of its link to the central government and an issuer-friendly environment to price the new note through its existing curve.

Israeli-American pharmaceutical company Teva ripped through a severely undersupplied European corporate bond market this week, making savage price cuts on all three tranches of a €4bn trade that still ground tighter in secondary markets. Ross Lancaster reports.

Teva Pharmaceuticals had the corporate dollar market in its thrall this week as it took advantage of US corporate earnings blackouts to print a $15bn M&A blockbuster that attracted nearly $70bn worth of orders.